This clinical trial is focused on studying a condition known as infectious pulmonary endotheliopathy, which affects the blood vessels in the lungs and can lead to severe breathing problems. The trial will explore the effects of a treatment using a medication called Ilomedin, which contains the active substance iloprost trometamol. This medication is given as a solution for infusion, meaning it is administered directly into the bloodstream over a period of time. The study will compare the effects of Ilomedin to a placebo to see if it can help reduce the risk of death within 28 days for patients who are on mechanical ventilation due to this lung condition.

The purpose of the study is to determine if a continuous infusion of Ilomedin at a specific dose can improve survival rates in patients with infectious pulmonary endotheliopathy. Participants in the study will receive the treatment for 72 hours while being closely monitored. The trial will also look at other factors, such as the number of days patients can live without needing additional support like vasopressors, which are medications that help maintain blood pressure, or mechanical ventilation, which is a machine that helps with breathing.

This study is important because it aims to find a potential new treatment option for patients with severe lung infections who require intensive care. By understanding the effects of Ilomedin, researchers hope to improve outcomes for these patients and provide better care in the future. The trial is expected to continue until 2026, with the goal of gathering enough information to make informed conclusions about the treatment’s effectiveness and safety.